Early stages in the ontogeny of small B-cell lymphomas: Genetics and microenvironment

P Ghia, B Nadel, B Sander, K Stamatopoulos, FK Stevenson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In this review, we focus on the mechanisms underlying lymphomagenesis in chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and splenic marginal zone lymphoma. The cells of origin of these small B-cell lymphomas are distinct, as are the characteristic chromosomal lesions and clinical courses. One shared feature is retention of expression of surface immunoglobulin. Analysis of this critical receptor reveals the point of differentiation reached by the cell of origin. Additionally, the sequence patterns of the immunoglobulin-variable domains can indicate a role for stimulants of the B-cell receptor before, during and after malignant transformation. The pathways driven via the B-cell receptor are now being targeted by specific kinase inhibitors with exciting clinical effects. To consider routes to pathogenesis, potentially offering earlier intervention, or to identify causative factors, genetic tools are being used to track pretransformation events and the early phases in lymphomagenesis. These methods are revealing that chromosomal changes are only one of the many steps involved, and that the influence of surrounding cells, probably multiple and variable according to tissue location, is required, both to establish tumours and to maintain growth and survival. Similarly, the influence of the tumour microenvironment may protect malignant cells from eradication by treatment, and the resulting minimal residual disease will eventually give rise to relapse. The common and different features of the four lymphomas will be summarized to show how normal B lymphocytes can be subverted to generate tumours, how these tumours evolve and how their weaknesses can be attacked by targeted therapies. © 2017 The Association for the Publication of the Journal of Internal Medicine.
Original languageEnglish
Pages (from-to)395-414
Number of pages20
JournalJournal of Internal Medicine
Volume282
Issue number5
DOIs
Publication statusPublished - 2017

Fingerprint

B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Lymphoma
Mantle-Cell Lymphoma
Neoplasms
B-Cell Antigen Receptors
Follicular Lymphoma
Tumor Microenvironment
Residual Neoplasm
Internal Medicine
Publications
Cell Differentiation
Phosphotransferases
Recurrence
Growth
Therapeutics

Cite this

Early stages in the ontogeny of small B-cell lymphomas: Genetics and microenvironment. / Ghia, P; Nadel, B; Sander, B; Stamatopoulos, K; Stevenson, FK.

In: Journal of Internal Medicine, Vol. 282, No. 5, 2017, p. 395-414.

Research output: Contribution to journalArticle

Ghia, P ; Nadel, B ; Sander, B ; Stamatopoulos, K ; Stevenson, FK. / Early stages in the ontogeny of small B-cell lymphomas: Genetics and microenvironment. In: Journal of Internal Medicine. 2017 ; Vol. 282, No. 5. pp. 395-414.
@article{4fc13c8dab5c4555833172d1c68adfee,
title = "Early stages in the ontogeny of small B-cell lymphomas: Genetics and microenvironment",
abstract = "In this review, we focus on the mechanisms underlying lymphomagenesis in chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and splenic marginal zone lymphoma. The cells of origin of these small B-cell lymphomas are distinct, as are the characteristic chromosomal lesions and clinical courses. One shared feature is retention of expression of surface immunoglobulin. Analysis of this critical receptor reveals the point of differentiation reached by the cell of origin. Additionally, the sequence patterns of the immunoglobulin-variable domains can indicate a role for stimulants of the B-cell receptor before, during and after malignant transformation. The pathways driven via the B-cell receptor are now being targeted by specific kinase inhibitors with exciting clinical effects. To consider routes to pathogenesis, potentially offering earlier intervention, or to identify causative factors, genetic tools are being used to track pretransformation events and the early phases in lymphomagenesis. These methods are revealing that chromosomal changes are only one of the many steps involved, and that the influence of surrounding cells, probably multiple and variable according to tissue location, is required, both to establish tumours and to maintain growth and survival. Similarly, the influence of the tumour microenvironment may protect malignant cells from eradication by treatment, and the resulting minimal residual disease will eventually give rise to relapse. The common and different features of the four lymphomas will be summarized to show how normal B lymphocytes can be subverted to generate tumours, how these tumours evolve and how their weaknesses can be attacked by targeted therapies. {\circledC} 2017 The Association for the Publication of the Journal of Internal Medicine.",
author = "P Ghia and B Nadel and B Sander and K Stamatopoulos and FK Stevenson",
year = "2017",
doi = "10.1111/joim.12608",
language = "English",
volume = "282",
pages = "395--414",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Early stages in the ontogeny of small B-cell lymphomas: Genetics and microenvironment

AU - Ghia, P

AU - Nadel, B

AU - Sander, B

AU - Stamatopoulos, K

AU - Stevenson, FK

PY - 2017

Y1 - 2017

N2 - In this review, we focus on the mechanisms underlying lymphomagenesis in chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and splenic marginal zone lymphoma. The cells of origin of these small B-cell lymphomas are distinct, as are the characteristic chromosomal lesions and clinical courses. One shared feature is retention of expression of surface immunoglobulin. Analysis of this critical receptor reveals the point of differentiation reached by the cell of origin. Additionally, the sequence patterns of the immunoglobulin-variable domains can indicate a role for stimulants of the B-cell receptor before, during and after malignant transformation. The pathways driven via the B-cell receptor are now being targeted by specific kinase inhibitors with exciting clinical effects. To consider routes to pathogenesis, potentially offering earlier intervention, or to identify causative factors, genetic tools are being used to track pretransformation events and the early phases in lymphomagenesis. These methods are revealing that chromosomal changes are only one of the many steps involved, and that the influence of surrounding cells, probably multiple and variable according to tissue location, is required, both to establish tumours and to maintain growth and survival. Similarly, the influence of the tumour microenvironment may protect malignant cells from eradication by treatment, and the resulting minimal residual disease will eventually give rise to relapse. The common and different features of the four lymphomas will be summarized to show how normal B lymphocytes can be subverted to generate tumours, how these tumours evolve and how their weaknesses can be attacked by targeted therapies. © 2017 The Association for the Publication of the Journal of Internal Medicine.

AB - In this review, we focus on the mechanisms underlying lymphomagenesis in chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and splenic marginal zone lymphoma. The cells of origin of these small B-cell lymphomas are distinct, as are the characteristic chromosomal lesions and clinical courses. One shared feature is retention of expression of surface immunoglobulin. Analysis of this critical receptor reveals the point of differentiation reached by the cell of origin. Additionally, the sequence patterns of the immunoglobulin-variable domains can indicate a role for stimulants of the B-cell receptor before, during and after malignant transformation. The pathways driven via the B-cell receptor are now being targeted by specific kinase inhibitors with exciting clinical effects. To consider routes to pathogenesis, potentially offering earlier intervention, or to identify causative factors, genetic tools are being used to track pretransformation events and the early phases in lymphomagenesis. These methods are revealing that chromosomal changes are only one of the many steps involved, and that the influence of surrounding cells, probably multiple and variable according to tissue location, is required, both to establish tumours and to maintain growth and survival. Similarly, the influence of the tumour microenvironment may protect malignant cells from eradication by treatment, and the resulting minimal residual disease will eventually give rise to relapse. The common and different features of the four lymphomas will be summarized to show how normal B lymphocytes can be subverted to generate tumours, how these tumours evolve and how their weaknesses can be attacked by targeted therapies. © 2017 The Association for the Publication of the Journal of Internal Medicine.

U2 - 10.1111/joim.12608

DO - 10.1111/joim.12608

M3 - Article

VL - 282

SP - 395

EP - 414

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 5

ER -